Physician profile
Daniel G Goddard
NPI 1942391289
$1,039.22
in general payments reported to CMS, 2019-2025
15 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $38.80 · 2021: $30.24 · 2022: $12.17 · 2023: $217 · 2024: $366 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $185.03 | 2023-2025 | |
| Exact Sciences Corporation | $181.88 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $144.28 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $99.64 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Sanofi-Aventis U.S. LLC | $80.25 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.22 | 2021-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $62.72 | 2024-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $57.95 | 2020-2023 | Mounjaro |
| Amarin Pharma, INC. | $39.32 | 2019 | |
| Inspire Medical Systems, INC. | $27.91 | 2023 | Inspire |
| Dexcom, INC. | $21.73 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $21.72 | 2019 | |
| Abbott Laboratories | $18.98 | 2019 | |
| Allergan, INC. | $11.72 | 2019 | |
| Boston Scientific Corporation | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goddard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.